靶向CD38的治疗多发性骨髓瘤新药:达拉木单抗

A new drug targeting CD38 in treatment of multiple myeloma: daratumumab

CD38在骨髓瘤细胞表面高表达。达拉木单抗(Dar)为一种人IgG1κ单克隆抗体,主要作用于CD38,通过直接诱导凋亡及通过免疫介导的肿瘤细胞裂解来抑制CD38表达肿瘤细胞的生长。Dar由杨森制药公司研发,已经在美国、日本和欧盟等国家和地区获批准用于治疗多发性骨髓瘤。临床试验表明,Dar单独应用对多发性骨髓瘤具有较好的治疗效果,与来那度胺或硼替佐米联用时效果更明显。Dar最常见的不良反应包括中性粒细胞下降、血小板减少、疲劳、恶心、腹泻、上呼吸道感染和输液反应等。

CD38 highly expresses on the surface of multiple myeloma ceils.Daratumumab is a humanized IgG1k monoclonal antibody that binds to CD38 and inhibits the growth of CD38 expressing tumor cells. Daratumumab was developed by Janssen Biotech and Genmab.It has been approved for the treatment of multiple myeloma in several countries,including the USA,Japan and those of the EU.Clinic trials have shown that daratumumab alone has a good therapeutic effect on multiple myeloma and is more effective when combined with lenalidomide or bortezomib.The most frequently adverse reactions of daratumumab are neutropenia, thrombocytopenia,fatigue,nausea,diarrhea,upper respiratory tract infection,infusion reactions,and so on.